Evidence map›Paper›PMID 35879507›Full record

ArticleThe journal of pathology. Clinical research2022

CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer.

Kathryn Af Pennel, Jean A Quinn, Colin Nixon, Jitwadee Inthagard, Hester C van Wyk, David Chang, Selma Rebus, GPOL Group, Jennifer Hay, Noori N Maka and 7 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Kathryn Af PennelWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0003-0186-1331
Jean A QuinnWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Colin NixonCRUK Beatson Institute, Glasgow, UK.
Jitwadee InthagardWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Hester C van WykDepartment of Surgery, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
David ChangWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Selma RebusWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
GPOL GroupGlasgow Precision Oncology Laboratory, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Jennifer HayGlasgow Tissue Research Facility, Queen Elizabeth University Hospital, Glasgow, UK.
Noori N MakaDepartment of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.
Campbell Sd RoxburghWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Paul G HorganDepartment of Surgery, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
Donald C McMillanWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
James H ParkDepartment of Surgery, Queen Elizabeth University Hospital, Glasgow, UK.ORCID 0000-0002-6551-2037
Antonia K RoseweirSchool of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.ORCID 0000-0001-6158-1564
Colin W SteeleCRUK Beatson Institute, Glasgow, UK.
Joanne EdwardsWolfson Wohl Cancer Research Institute, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-7192-6906
Glasgow Royal Infirmary · GBUniversity of Glasgow · GBQueen Elizabeth University Hospital · GBCancer Research UK Scotland Institute · GB

Funding

Cancer Research UKChief Scientist Office PCL/17/03Medical Research Council
6 · The paper itself

Abstract

CXCL8 is an inflammatory chemokine elevated in the colorectal cancer (CRC) tumour microenvironment. CXCR2, the major receptor for CXCL8, is predominantly expressed by neutrophils. In the cancer setting, CXCL8 plays important roles in neutrophil chemotaxis, facilitating angiogenesis, invasion, and metastasis. This study aimed to assess the spatial distribution of CXCL8 mRNA expression in CRC specimens, explore associations with clinical characteristics, and investigate the underlying biology of aberrant CXCL8 levels. CXCR2 expression was also assessed in a second cohort of unique CRC primary tumours and synchronously resected matched liver metastases. A previously constructed tissue microarray consisting of a cohort of stage I-IV CRC patients undergoing surgical resection with curative intent (n = 438) was probed for CXCL8 via RNAscope®. Analysis was performed using HALO® digital pathology software to quantify expression in the tumour and stromal compartments. Scores were assessed for association with clinical characteristics. Mutational analyses were performed on a subset of these patients to determine genomic differences in patients with high CXCL8 expression. A second cohort of stage IV CRC patients with primary and matched metastatic liver tumours was stained via immunohistochemistry for CXCR2, and scores were assessed for clinical significance. CXCL8 expression within the stromal compartment was associated with reduced cancer-specific survival in the first cohort (p = 0.035), and this relationship was potentiated in right-sided colon cancer cases (p = 0.009). High CXCL8 within the stroma was associated with driving a more stromal-rich phenotype and the presence of metastases. When stromal CXCL8 scores were combined with tumour-infiltrating macrophage counts or systemic neutrophil counts, patients classified as high for both markers had significantly poorer prognosis. CXCR2+ immune cell infiltration was associated with increased stromal invasion in liver metastases (p = 0.037). These data indicate a role for CXCL8 in driving unfavourable tumour histological features and promoting metastases. This study suggests that inhibiting CXCL8/CXCR2 should be investigated in patients with right-sided colonic disease and stroma-rich tumours.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHumansImmunohistochemistryRNA, MessengerTumor MicroenvironmentRNA, Messengercolorectal cancerCXCL8CXCR2metastasessidednessstromal invasiontumour microenvironment

Identifiers

PMID35879507
PMCPMC9535100
OpenAlexW4287833983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.